Table 1 Cohort description
Variables | n | % |
|---|---|---|
ER | Â | Â |
Negative | 14 | 51.9% |
Positive | 9 | 33.3% |
Unknown | 4 | 14.8% |
PR | Â | Â |
Negative | 18 | 66.7% |
Positive | 5 | 18.5% |
Unknown | 4 | 14.8% |
Run-in Treatment | Â | Â |
Trastuzumab | 17 | 63.0% |
Nab-paclitaxel | 10 | 37.0% |
Response | Â | Â |
PathCR | 13 | 48.1% |
No PathCR | 10 | 37.0% |
Unknown | 4 | 14.8% |